Multiple related companies have responded! Institution: The enthusiasm for the future track will be further ignited, and the concept of weight loss pills will soar
Yesterday, the concept of weight loss drugs in A-shares surged, with Changshan Pharmaceutical hitting the limit up by 20cm, Hanyu Pharmaceutical hitting the limit up by more than 13%, Dezhan Health hitting the limit up, Zhenguang Pharmaceutical hitting the limit up by nearly 8%, Jinkai Shengke hitting the limit up by more than 7%, and stocks such as Huasen Pharmaceutical, Nuotai Biotechnology, Ruizhi Pharmaceutical, and Haofan Biotechnology following suit.
On the news front, Novo Nordisk and Lilly continue to rise and break new historical highs. JPMorgan Chase has raised its sales forecast for weight loss drugs, predicting that annual sales of GLP-1 receptor agonist related drugs will exceed $100 billion by 2030. Meanwhile, JPMorgan Chase also predicts that the market size of weight loss drugs in China is expected to reach $14.9 billion by 2030.
Multiple listed companies have responded to the business situation related to weight loss drugs. Today, a reporter from First Financial called the investor hotline of Changshan Pharmaceutical as an investor, and the staff stated that the company has products similar to Smegglutide and is expected to submit a registration application by the end of the year; Hongbo Pharmaceutical stated on the interactive platform that its team has the ability to synthesize liquid phase peptides and solid-phase peptides; Huadong Pharmaceutical stated on the interactive platform that the company's Smegglutide Injection has completed Phase I clinical trials and reached the endpoint of equivalence studies, and Phase III clinical trials have been initiated.
According to a research report by CITIC Securities, with the positive results of GLP-1 drugs in multiple preliminary clinical studies and further deepening of related basic research, GLP-1 drugs are expected to provide effective treatment for more people with indications in the future. We believe that GLP-1 drugs can benefit patients in multiple indications, with a large therapeutic population and broad potential market space. With the expansion of GLP-1 drugs to multiple indications, the enthusiasm for the future track is expected to be further ignited.
Founder Securities stated that overseas sales of GLP-1 innovative drugs have continued to exceed expectations, leading to a hot global GLP-1 drug research and development market. Various multi target and oral formulations have launched clinical trials, resulting in the rapid development of the peptide industry chain and giving recommended ratings to the industry.